T Cell-Targeted Immunotherapy for the Prevention & Treatment of Long COVID
- Persistent virus reservoirs associated with dysfunctional anti-viral T cell responses is a root cause of Long COVID, a debilitating disease affecting >400 million people globally
- We have developed an mRNA-based immunotherapeutic targeting protective T cell antigens of SARS-CoV-2
- Treatment of Long COVID in mice resulted in reversal of T cell dysfunction, clearance of virus reservoirs, and amelioration of cognitive and behavioural deficits